While fingolimod is a well-established disease-modifying therapy (DMT) known for its sphingosine-1-phosphate receptor modulation, its impact on immune pathways at the molecular level—particularly in relation to MS progression and neuroimaging results—remains incompletely understood. Here, S1PR1 is linked to myeloid sarcoma.